PURPOSE:Single-cycle melphalan 200 mg/m2 and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free survival (PFS) and overall survival (OS) for transplantation-eligible patients with multiple myeloma (MM). We designed a prospective, randomized, phase III study to test additional interventions to improve PFS by comparing AHCT, tandem AHCT (AHCT/AHCT), and AHCT and four subsequent cycles of len, bortezomib, and dexamethasone (RVD; AHCT + RVD), all followed by len until disease progression. PATIENTS AND METHODS: Patients with symptomatic MM within 12 months from starting therapy and without progression who were age 70 years or younger were randomly assigned to AHCT/AHCT + len (n = 247), AHCT + RVD + len (n = 254), or AHCT + len (n = 257). The primary end point was 38-month PFS. RESULTS:The study population had a median age of 56 years (range, 20 to 70 years); 24% of patients had high-risk MM, 73% had a triple-drug regimen as initial therapy, and 18% were in complete response at enrollment. The 38-month PFS rate was 58.5% (95% CI, 51.7% to 64.6%) for AHCT/AHCT + len, 57.8% (95% CI, 51.4% to 63.7%) for AHCT + RVD + len, and 53.9% (95% CI, 47.4% to 60%) for AHCT + len. For AHCT/AHCT + len, AHCT + RVD + len, and AHCT + len, the OS rates were 81.8% (95% CI, 76.2% to 86.2%), 85.4% (95% CI, 80.4% to 89.3%), and 83.7% (95% CI, 78.4% to 87.8%), respectively, and the complete response rates at 1 year were 50.5% (n = 192), 58.4% (n = 209), and 47.1% (n = 208), respectively. Toxicity profiles and development of second primary malignancies were similar across treatment arms. CONCLUSION: Second AHCT or RVD consolidation as post-AHCT interventions for the up-front treatment of transplantation-eligible patients with MM did not improve PFS or OS. Single AHCT and len should remain as the standard approach for this population.
RCT Entities:
PURPOSE: Single-cycle melphalan 200 mg/m2 and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free survival (PFS) and overall survival (OS) for transplantation-eligible patients with multiple myeloma (MM). We designed a prospective, randomized, phase III study to test additional interventions to improve PFS by comparing AHCT, tandem AHCT (AHCT/AHCT), and AHCT and four subsequent cycles of len, bortezomib, and dexamethasone (RVD; AHCT + RVD), all followed by len until disease progression. PATIENTS AND METHODS: Patients with symptomatic MM within 12 months from starting therapy and without progression who were age 70 years or younger were randomly assigned to AHCT/AHCT + len (n = 247), AHCT + RVD + len (n = 254), or AHCT + len (n = 257). The primary end point was 38-month PFS. RESULTS: The study population had a median age of 56 years (range, 20 to 70 years); 24% of patients had high-risk MM, 73% had a triple-drug regimen as initial therapy, and 18% were in complete response at enrollment. The 38-month PFS rate was 58.5% (95% CI, 51.7% to 64.6%) for AHCT/AHCT + len, 57.8% (95% CI, 51.4% to 63.7%) for AHCT + RVD + len, and 53.9% (95% CI, 47.4% to 60%) for AHCT + len. For AHCT/AHCT + len, AHCT + RVD + len, and AHCT + len, the OS rates were 81.8% (95% CI, 76.2% to 86.2%), 85.4% (95% CI, 80.4% to 89.3%), and 83.7% (95% CI, 78.4% to 87.8%), respectively, and the complete response rates at 1 year were 50.5% (n = 192), 58.4% (n = 209), and 47.1% (n = 208), respectively. Toxicity profiles and development of second primary malignancies were similar across treatment arms. CONCLUSION: Second AHCT or RVD consolidation as post-AHCT interventions for the up-front treatment of transplantation-eligible patients with MM did not improve PFS or OS. Single AHCT and len should remain as the standard approach for this population.
Authors: A Palumbo; S Triolo; C Argentino; S Bringhen; A Dominietto; C Rus; P Omedè; C Tarella; A Pileri; M Boccadoro Journal: Blood Date: 1999-08-15 Impact factor: 22.113
Authors: Philip L McCarthy; Sarah A Holstein; Maria Teresa Petrucci; Paul G Richardson; Cyrille Hulin; Patrizia Tosi; Sara Bringhen; Pellegrino Musto; Kenneth C Anderson; Denis Caillot; Francesca Gay; Philippe Moreau; Gerald Marit; Sin-Ho Jung; Zhinuan Yu; Benjamin Winograd; Robert D Knight; Antonio Palumbo; Michel Attal Journal: J Clin Oncol Date: 2017-07-25 Impact factor: 44.544
Authors: B Barlogie; S Jagannath; D H Vesole; S Naucke; B Cheson; S Mattox; D Bracy; S Salmon; J Jacobson; J Crowley; G Tricot Journal: Blood Date: 1997-02-01 Impact factor: 22.113
Authors: M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille Journal: N Engl J Med Date: 1996-07-11 Impact factor: 91.245
Authors: M Cavo; L Pantani; A Pezzi; M T Petrucci; F Patriarca; F Di Raimondo; G Marzocchi; M Galli; V Montefusco; E Zamagni; B Gamberi; P Tacchetti; A Brioli; A Palumbo; P Sonneveld Journal: Leukemia Date: 2015-10-07 Impact factor: 11.528
Authors: Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker Journal: N Engl J Med Date: 2012-05-10 Impact factor: 91.245
Authors: Sarah A Holstein; Vera J Suman; Kouros Owzar; Katelyn Santo; Don M Benson; Thomas C Shea; Thomas Martin; Margarida Silverman; Luis Isola; Ravi Vij; Bruce D Cheson; Charles Linker; Kenneth C Anderson; Paul G Richardson; Philip L McCarthy Journal: Biol Blood Marrow Transplant Date: 2020-04-20 Impact factor: 5.742
Authors: Neeraj Saini; Qaiser Bashir; Denái R Milton; Guilin Tang; Ruby Delgado; Gabriela Rondon; Uday R Popat; Chitra M Hosing; Yago Nieto; Partow Kebriaei; Amin M Alousi; Rohtesh Mehta; Samer Srour; Issa F Khouri; Donna M Weber; Sheeba K Thomas; Hans C Lee; Krina K Patel; Robert Z Orlowski; Richard E Champlin; Muzaffar H Qazilbash Journal: Blood Adv Date: 2020-10-13
Authors: Laura Rosiñol; Albert Oriol; Rafael Rios; Anna Sureda; María Jesús Blanchard; Miguel Teodoro Hernández; Rafael Martínez-Martínez; Jose M Moraleda; Isidro Jarque; Juan Bargay; Mercedes Gironella; Felipe de Arriba; Luis Palomera; Yolanda González-Montes; Josep M Martí; Isabel Krsnik; Jose M Arguiñano; Maria Esther González; Ana Pilar González; Luis Felipe Casado; Lucia López-Anglada; Bruno Paiva; Maria-Victoria Mateos; Jesus F San Miguel; Juan-José Lahuerta; Joan Bladé Journal: Blood Date: 2019-10-17 Impact factor: 22.113
Authors: Pashna N Munshi; David Vesole; Artur Jurczyszyn; Jan Maciej Zaucha; Andrew St Martin; Omar Davila; Vaibhav Agrawal; Sherif M Badawy; Minoo Battiwalla; Saurabh Chhabra; Edward Copelan; Mohamed A Kharfan-Dabaja; Nosha Farhadfar; Siddhartha Ganguly; Shahrukh Hashmi; Maxwell M Krem; Hillard M Lazarus; Ehsan Malek; Kenneth Meehan; Hemant S Murthy; Taiga Nishihori; Rebecca L Olin; Richard F Olsson; Jeffrey Schriber; Sachiko Seo; Gunjan Shah; Melhem Solh; Jason Tay; Shaji Kumar; Muzaffar H Qazilbash; Nina Shah; Parameswaran N Hari; Anita D'Souza Journal: Cancer Date: 2020-09-23 Impact factor: 6.860